MedTrace Logo

Investigation of the Efficacy of Zesteem in Accelerating Early Wound Healing

NCT00984386 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2009-09-25

No results posted yet for this study

Summary

The purpose of this study is to investigate early wound healing of one application of four different doses of intradermal Zesteem (17β-Estradiol) in male subjects and female subjects two years post-menopausal.

Conditions

  • Cicatrix
  • Wound-healing

Interventions

DRUG

Zesteem

Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy

DRUG

Zesteem

Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy

DRUG

Zesteem

Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy

DRUG

Zesteem

Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy

DRUG

Placebo

Intradermal placebo, 100μl administered once before punch biopsy

Sponsors & Collaborators

  • Renovo

    lead INDUSTRY

Principal Investigators

  • Jonathan Duncan · Renovo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-04-30
Completion
2005-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984386 on ClinicalTrials.gov